By Fineline Cube 
AstraZeneca plc (NYSE: AZN) has secured marketing approval from China’s National Medical Products Administration (NMPA) for Imjudo (tremelimumab). The CTLA-4 inhibitor is approved for use in combination with Imfinzi (durvalumab) and platinum-based chemotherapy as a first-line treatment for adults with metastatic non-small cell lung cancer (NSCLC) whose tumors are negative for EGFR sensitive mutations and ALK alterations.
Regulatory Approval & Clinical Basis
| Component | Detail |
|---|---|
| Regimen | Imjudo (tremelimumab) + Imfinzi (durvalumab) + Platinum Chemotherapy |
| Indication | 1L metastatic NSCLC (EGFR-/ALK-) |
| Basis for Approval | Phase III POSEIDON clinical trial |
| Dosing Schedule | Tremelimumab: 5 cycles; Durvalumab + Chemo: 4 cycles |
POSEIDON Trial Key Results
| Endpoint | Combination Regimen | Chemotherapy Alone | Hazard Ratio (HR) | p-value |
|---|---|---|---|---|
| Overall Survival (OS) | Median 14.0 months; 2-year rate ~33% | Median 11.7 months; 2-year rate 22% | HR 0.77 (95% CI: 0.65–0.92) | 0.00304 |
| Progression-Free Survival (PFS) | Significant improvement | — | HR 0.72 (95% CI: 0.60–0.86) | 0.00031 |
| Safety | Consistent with known profiles of Imjudo and Imfinzi; no new safety signals identified |
Drug Mechanism & Strategic Context
- Mechanism of Action: Tremelimumab, a first-generation anti-CTLA-4 monoclonal antibody (originally from Pfizer), blocks the CTLA-4 checkpoint on T-cells, thereby enhancing their activation and anti-tumor immune response.
- Differentiated IO Approach: This approval establishes AstraZeneca’s unique STRIDE regimen (Single Tremelimumab Regular Interval Durvalumab) in China, differentiating it from other PD-(L)1-based combinations by adding a short course of CTLA-4 inhibition for a potent, yet time-limited, immune boost.
- Addressing High Unmet Need: The approval provides a new, more effective standard of care for the large population of Chinese NSCLC patients without actionable EGFR or ALK drivers, who have historically relied on chemotherapy alone.
Market Impact
- Competitive Edge: The significant 23% reduction in risk of death and improved long-term survival rates position the Imjudo/Imfinzi combo as a highly compelling option in the crowded first-line NSCLC market.
- Franchise Expansion: This approval significantly broadens the commercial footprint of AstraZeneca’s immuno-oncology franchise in China, leveraging the established presence of Imfinzi.
- Global Validation: The NMPA’s decision, based on the global POSEIDON data, reinforces the regimen’s efficacy and safety, supporting its adoption as a new global standard of care.
Forward-Looking Statements
This brief reports on a marketing approval from the NMPA. Commercial success is subject to pricing, reimbursement, and market acceptance. Prescribing information is based on the POSEIDON trial and is subject to change.-Fineline Info & Tech